Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2005

View Archived Issues

Schering-Plough highlights first quarter developments

G-207 studied in malignant glioma

NX-1207 shows long-term efficacy in improving the symptoms of BPH

Phase II study investigates ginger for CINV

Dosing begins in phase I trial of Hedgehog antagonist for basal cell carcinoma

Harnal D launched in Japan

Chugai subsidiary renamed

FDA extends action date for SomatoKine NDA

MicroRNAs: potential novel human oncogenes

Further study required for Sativex approval in U.K.

IPI-504 studied in relapsed and relapsed refractory multiple myeloma

Spotlight on PTSD

Phase I results discussed for Sinovac's SARS vaccine

Fast track designation for Laszarin for heart failure in diabetes patients

NIP-004: Novel thrombopoietin mimetic small-molecule compound

Combi-molecule targets Bcr-Abl kinase and damages DNA

Lyrica approved as add-on treatment for partial onset seizures

Zmax single-dose antibiotic receives FDA approval

Long-term effects reported for febuxostat in hyperuricemia and gout

Clazosentan acts as a potent competitive ETA receptor antagonist

NVP-AEW-541 studied for treatment of musculoskeletal tumors

Recent patent discloses novel immunosuppressive agents

Iloprost and bosentan reduce mortality in PPH patients waiting for a transplant

Novel therapeutics for cardiovascular diseases reported in recent patents

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

MCI-196 decreases serum phosphate and cholesterol levels of hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...